Risk reduction strategies like a bilateral prophylactic mastectomy, bilateral salpingo-oophorectomy, and tamoxifen is done in which conditions?
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive information from multiple authoritative textbooks. Here is a detailed, well-structured answer:
Risk Reduction Strategies: Bilateral Prophylactic Mastectomy, Bilateral Salpingo-Oophorectomy, and Tamoxifen
These interventions are offered to individuals at significantly elevated (high) risk of breast and/or ovarian cancer - primarily those with hereditary cancer predispositions. They are not offered to the general population.
1. Bilateral Prophylactic Mastectomy (BPM)
Primary indications:
| Condition | Risk Level |
|---|---|
| BRCA1 or BRCA2 mutation carriers | Very high (~70-85% lifetime breast cancer risk) |
| PALB2, PTEN, ATM, CHEK2 mutation carriers | High (data less robust, individualized decision) |
| Li-Fraumeni syndrome (TP53 mutation) | High lifetime risk |
| Cowden syndrome (PTEN mutation) | High lifetime risk |
| Strong family history (multiple first-degree relatives with breast cancer) without identified mutation | Moderate-to-high risk |
| Lobular carcinoma in situ (LCIS) | Increased risk marker |
| Contralateral prophylactic mastectomy in a newly diagnosed breast cancer patient with BRCA mutation | Risk of second primary cancer |
Efficacy:
- Reduces breast cancer risk by 90% in high-risk women (Hartmann et al., 1999).
- A meta-analysis of 2,555 BRCA1/2 carriers showed an 89% risk reduction with BPM.
- No statistically significant improvement in all-cause mortality with BPM alone, unlike prophylactic bilateral salpingo-oophorectomy (PBSO).
(Sabiston Textbook of Surgery, p. 2148-2152)
Contraindications to contralateral prophylactic mastectomy (CPM):
- Average-risk women with unilateral sporadic breast cancer
- Advanced primary cancer (T4, N3, or stage IV)
- High postoperative complication risk
- BRCA-negative patients in BRCA-positive families
- Males with breast cancer
2. Bilateral Salpingo-Oophorectomy (BSO / Risk-Reducing Salpingo-Oophorectomy, RRSO)
Primary indications:
| Condition | Details |
|---|---|
| BRCA1 mutation carriers | ~40-46% lifetime ovarian cancer risk; BSO recommended at age 35-40, or after childbearing is complete |
| BRCA2 mutation carriers | ~10-27% lifetime ovarian cancer risk; BSO recommended at age 40-45 |
| PALB2, RAD51C, RAD51D, BRIP1 mutation carriers | Elevated ovarian cancer risk; individualized recommendation |
| Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) | Elevated ovarian + endometrial cancer risk; BSO often recommended after childbearing |
| Creasy & Resnik: RRBSO | Recommended at age 35 or completion of childbearing in BRCA carriers |
Efficacy:
- 36% relative risk reduction in ovarian/primary peritoneal cancer incidence in BRCA mutation carriers (Harrison's Principles of Internal Medicine 22E).
- Additionally reduces breast cancer risk by ~45-50% (relative risk ~0.50) in BRCA carriers, especially when done before age 45-50.
- A meta-analysis in 7,323 BRCA1/2 carriers showed prophylactic BSO reduces breast cancer risk by 45% (Sabiston Textbook of Surgery).
Important caveat: Even after BSO, peritoneal carcinomas can still occur in 2-3% of women, as the entire peritoneum carries risk. There is also an increased risk of cardiovascular disease when BSO is done in premenopausal women.
(Harrison's Principles of Internal Medicine 22E, p. 192-194; Sabiston Textbook of Surgery, p. 2150)
3. Tamoxifen (Chemoprevention / Risk Reduction)
Tamoxifen is a selective estrogen receptor modulator (SERM) approved by the FDA for breast cancer risk reduction.
Indications (who qualifies):
| Criterion | Details |
|---|---|
| 5-year Gail model risk ≥1.66-1.7% (Gail relative risk ≥1.66%) | Women age 35-59 years |
| Women aged ≥60 years | All such women qualify, regardless of Gail score |
| Lobular carcinoma in situ (LCIS) | Tamoxifen gives a 59% risk reduction in this group |
| Atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) | 75% risk reduction with tamoxifen |
| DCIS post-mastectomy | Reduces risk of invasive disease |
| BRCA1/2 mutation carriers | May be used as an option, though surgical prevention is usually favored |
Key trials:
- NSABP P-1 trial (13,388 women): Tamoxifen 20 mg/day x 5 years reduced invasive breast cancer incidence by 49% (risk reduction only for ER-positive cancers).
- IBIS-I trial: 32% reduction in breast cancer incidence.
- STAR trial (NSABP P-2): Raloxifene was nearly equivalent to tamoxifen, but with a more favorable toxicity profile (45% less endometrial cancer, 25% fewer thromboembolic events).
Side effects that limit use:
- Endometrial cancer (2.5x higher risk, postmenopausal women)
- Deep vein thrombosis (1.6x higher)
- Pulmonary embolism (3.0x higher)
- Cataracts / cataract surgery (nearly 2x more frequent)
- Vasomotor symptoms (hot flashes)
Note: A reduced-dose option of tamoxifen 5 mg/day x 3 years is available for those who are symptomatic or cannot tolerate the standard dose.
(Sabiston Textbook of Surgery, p. 2103-2143; Schwartz's Principles of Surgery, p. 89-97)
Summary Table
| Intervention | Primary Conditions |
|---|---|
| Bilateral prophylactic mastectomy | BRCA1/2 mutations, PALB2/PTEN/ATM/CHEK2 mutations, Li-Fraumeni, Cowden syndrome, strong family history, LCIS |
| Bilateral salpingo-oophorectomy | BRCA1/2 mutations (primary), Lynch syndrome, PALB2/RAD51C/RAD51D/BRIP1 mutations |
| Tamoxifen | Gail risk ≥1.66% (age 35-59), age ≥60, LCIS, ADH, ALH, DCIS post-mastectomy |
The common thread across all three is elevated heritable or histologic risk, with BRCA1/BRCA2 mutations being the most compelling indication for surgical risk reduction, while tamoxifen targets a broader population of women with modestly elevated breast cancer risk.
This is a shared conversation. Sign in to Orris to start your own chat.